Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick G Morris

Showing results (71-80 of 99) with videos related to

Pageof 10
Sort By:
Cancer|September 17, 2013
Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancerPatrick G Morris, Neil M Iyengar, Sujata Patil, et al.
Journal of Structural Biology|December 10, 2017
Correlative imaging reveals physiochemical heterogeneity of microcalcifications in human breast carcinomasJennie A M R Kunitake, Siyoung Choi, Kayla X Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2011
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinibPatrick G Morris, Carol Chen, Richard Steingart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fractionPatrick G Morris, Maura Dickler, Heather L McArthur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcomePatrick G Morris, Denise D Correa, Joachim Yahalom, et al.
Lung Cancer (Amsterdam, Netherlands)|May 8, 2022
Exhaled Breath Condensate (EBC) analysis of circulating tumour DNA (ctDNA) using a lung cancer specific UltraSEEK oncogene panelDaniel J Ryan, Sinead Toomey, Robert Smyth, et al.
The Oncologist|August 26, 2025
Implementation of Neoadjuvant Immunotherapy in Stage III Melanoma: A Modified Delphi Consensus Study in a European-accredited cancer Centre in IrelandChristopher Cronin, Fiachra Martin, James D Martin-Smith, et al.
International Journal of Dermatology|September 12, 2025
Cutaneous Immune-Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors for Patients With Advanced Solid Organ MalignanciesDavid O'Reilly, Gregg Murray, Orla M Fitzpatrick, et al.
Renal Failure|July 2, 2020
The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipientsSusan L Murray, Fergus E Daly, Patrick O'Kelly, et al.
Clinical Breast Cancer|December 12, 2025
Do Not Rush to Omit Sentinel Lymph Node Biopsy for Early Breast Cancer PatientsNíamh M Smyth, Alexandra M Zaborowski, Bukola V Bolarinwa, et al.
Pageof 10

Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
Cancer|September 17, 2013
Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancerPatrick G Morris, Neil M Iyengar, Sujata Patil, et al.
Journal of Structural Biology|December 10, 2017
Correlative imaging reveals physiochemical heterogeneity of microcalcifications in human breast carcinomasJennie A M R Kunitake, Siyoung Choi, Kayla X Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2011
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinibPatrick G Morris, Carol Chen, Richard Steingart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fractionPatrick G Morris, Maura Dickler, Heather L McArthur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcomePatrick G Morris, Denise D Correa, Joachim Yahalom, et al.
Lung Cancer (Amsterdam, Netherlands)|May 8, 2022
Exhaled Breath Condensate (EBC) analysis of circulating tumour DNA (ctDNA) using a lung cancer specific UltraSEEK oncogene panelDaniel J Ryan, Sinead Toomey, Robert Smyth, et al.
The Oncologist|August 26, 2025
Implementation of Neoadjuvant Immunotherapy in Stage III Melanoma: A Modified Delphi Consensus Study in a European-accredited cancer Centre in IrelandChristopher Cronin, Fiachra Martin, James D Martin-Smith, et al.
International Journal of Dermatology|September 12, 2025
Cutaneous Immune-Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors for Patients With Advanced Solid Organ MalignanciesDavid O'Reilly, Gregg Murray, Orla M Fitzpatrick, et al.
Renal Failure|July 2, 2020
The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipientsSusan L Murray, Fergus E Daly, Patrick O'Kelly, et al.
Clinical Breast Cancer|December 12, 2025
Do Not Rush to Omit Sentinel Lymph Node Biopsy for Early Breast Cancer PatientsNíamh M Smyth, Alexandra M Zaborowski, Bukola V Bolarinwa, et al.
Pageof 10